Other · developed by UroGen Pharma, Inc., a subsidiary of UroGen Pharma
UGN-501 is administered by intravesical instillation into the bladder. It is being studied in non-muscle invasive bladder cancer, including urothelial carcinoma in situ and recurrent urothelial carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07725796 | Phase 1 | Bladder (Urothelial, Transitional Cell) Cancer | Recruiting | URGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder (Urothelial, Transitional Cell) CancerNMIBCNon-muscle Invasive Bladder Cancer (NMIBC)Non-Muscle Invasive Bladder CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma in SituUrothelial Carcinoma of the Urinary BladderUrothelial Carcinoma Recurrent
Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.
See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
URGN catalysts and pipeline →